Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bogdanovic

Showing results (711-720 of 750) with videos related to

Pageof 75
Sort By:
Ebiomedicine|December 3, 2021
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialPeter Bergman, Ola Blennow, Lotta Hansson, et al.
Leukemia|August 30, 2016
Treatment and outcome of 2904 CML patients from the EUTOS population-based registryV S Hoffmann, M Baccarani, J Hasford, et al.
Nature Communications|April 10, 2025
Early-life gut microbiome associates with positive vaccine take and shedding in neonatal schedule of the human neonatal rotavirus vaccine RV3-BBJosef Wagner, Amanda Handley, Celeste M Donato, et al.
Nature Genetics|January 19, 2002
Mutant chromatin remodeling protein SMARCAL1 causes Schimke immuno-osseous dysplasiaCornelius F Boerkoel, Hiroshi Takashima, Joy John, et al.
Med (New York, N.Y.)|January 25, 2022
Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individualsKatie Healy, Elisa Pin, Puran Chen, et al.
Leukemia|March 19, 2015
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European CountriesV S Hoffmann, M Baccarani, J Hasford, et al.
Clinical Immunology (Orlando, Fla.)|October 27, 2015
Lack of IL7Rα expression in T cells is a hallmark of T-cell immunodeficiency in Schimke immuno-osseous dysplasia (SIOD)Mrinmoy Sanyal, Marie Morimoto, Alireza Baradaran-Heravi, et al.
Blood|June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisNaveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.
Acta Neuropathologica|February 3, 2009
Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe ConsortiumIrina Alafuzoff, Dietmar R Thal, Thomas Arzberger, et al.
Cell|September 27, 2020
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19Takuya Sekine, André Perez-Potti, Olga Rivera-Ballesteros, et al.
Pageof 75

Showing results (711-720 of 750) with videos related to

Sort By:
Pageof 75
Ebiomedicine|December 3, 2021
Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trialPeter Bergman, Ola Blennow, Lotta Hansson, et al.
Leukemia|August 30, 2016
Treatment and outcome of 2904 CML patients from the EUTOS population-based registryV S Hoffmann, M Baccarani, J Hasford, et al.
Nature Communications|April 10, 2025
Early-life gut microbiome associates with positive vaccine take and shedding in neonatal schedule of the human neonatal rotavirus vaccine RV3-BBJosef Wagner, Amanda Handley, Celeste M Donato, et al.
Nature Genetics|January 19, 2002
Mutant chromatin remodeling protein SMARCAL1 causes Schimke immuno-osseous dysplasiaCornelius F Boerkoel, Hiroshi Takashima, Joy John, et al.
Med (New York, N.Y.)|January 25, 2022
Salivary IgG to SARS-CoV-2 indicates seroconversion and correlates to serum neutralization in mRNA-vaccinated immunocompromised individualsKatie Healy, Elisa Pin, Puran Chen, et al.
Leukemia|March 19, 2015
The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European CountriesV S Hoffmann, M Baccarani, J Hasford, et al.
Clinical Immunology (Orlando, Fla.)|October 27, 2015
Lack of IL7Rα expression in T cells is a hallmark of T-cell immunodeficiency in Schimke immuno-osseous dysplasia (SIOD)Mrinmoy Sanyal, Marie Morimoto, Alireza Baradaran-Heravi, et al.
Blood|June 30, 2026
TRANSFORM-1 Phase 3 study: Efficacy and safety of navitoclax plus ruxolitinib in patients with untreated myelofibrosisNaveen Pemmaraju, Adam J Mead, Tim C P Somervaille, et al.
Acta Neuropathologica|February 3, 2009
Assessment of beta-amyloid deposits in human brain: a study of the BrainNet Europe ConsortiumIrina Alafuzoff, Dietmar R Thal, Thomas Arzberger, et al.
Cell|September 27, 2020
Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19Takuya Sekine, André Perez-Potti, Olga Rivera-Ballesteros, et al.
Pageof 75